Teriparatide or alendronate in glucocorticoid-induced osteoporosis

N Engl J Med. 2007 Nov 15;357(20):2028-39. doi: 10.1056/NEJMoa071408.


Background: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term glucocorticoids and are at high risk for fracture are lacking.

Methods: In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine. Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety.

Results: At the last measurement, the mean (+/-SE) bone mineral density at the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% vs. 3.7%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium.

Conclusions: Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alendronate / adverse effects
  • Alendronate / pharmacology
  • Alendronate / therapeutic use*
  • Biomarkers / blood
  • Bone Density / drug effects*
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / pharmacology
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Remodeling / drug effects
  • Calcium / blood
  • Double-Blind Method
  • Female
  • Fractures, Bone / epidemiology
  • Fractures, Bone / prevention & control
  • Glucocorticoids / adverse effects*
  • Humans
  • Lumbar Vertebrae / drug effects
  • Lumbar Vertebrae / physiology
  • Male
  • Middle Aged
  • Osteoporosis / chemically induced
  • Osteoporosis / drug therapy*
  • Risk
  • Teriparatide / adverse effects
  • Teriparatide / pharmacology
  • Teriparatide / therapeutic use*


  • Biomarkers
  • Bone Density Conservation Agents
  • Glucocorticoids
  • Teriparatide
  • Calcium
  • Alendronate

Associated data

  • ClinicalTrials.gov/NCT00051558